Table 1 Demographic and perioperative characteristics of the included patients.
Variable | Value |
|---|---|
Basic demographics | Patients (n = 35) |
Sex (M/F) | 21/14 |
Age (years, median, IQR) | 66.70 (53.4–78.20) |
BMI (kg/m², median, IQR) | 27.80 (24.97–31.14) |
Preoperative clinical scores | |
MELD-Na (median, IQR) | 8.00 (6.00–10.00) |
APRI (median, IQR) | 0.40 (0.20–0.70) |
CTP (median, IQR) | 5.00 (5.00–5.00) |
ICG-R15 (median, IQR) | 5.9 (3.05–7.95) |
Patients having received chemotherapy (%) | 26 (74%) |
Patients with Oxaliplatin-based chemotherapy | 20 |
Patients with Irinotecan-based chemotherapy | 6 |
Patients with Cirrhosis (%) | 4 (11%) |
FLR Metavir Score by ultrasound 2D-SWE | Patients (n = 31) |
F0 | 9 |
F1 | 1 |
F2 | 13 |
F3 | 4 |
F4 | 4 |
Tumor | Patients (n = 35) |
Neuroendocrine tumor metastasis (%) | 1 (2.9%) |
Colorectal carcinoma metastasis (%) | 13 (37.1%) |
HCC (%) | 8 (22.8%) |
IHCC (%) | 6 (17.1%) |
Renal cell carcinoma metastasis (%) | 1 (2.9%) |
Squamous cell carcinoma metastasis (%) | 2 (5.7%) |
Gallbladder carcinoma (%) | 2 (5.7%) |
Hemangioma (%) | 1 (2.9%) |
Pancreatic carcinoma metastasis (%) | 1 (2.9%) |
